Quest Diagnostics Incorporated
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 10.79B | 9.88B | 9.25B | 9.87B | 11.04B | 11.8% | |
| Cost of Revenue | (6.58B) | (6.45B) | (6.20B) | (6.63B) | (7.51B) | 13.3% | |
Gross Profit | 4.21B | 3.43B | 3.07B | 3.24B | 3.52B | 8.6% | |
| Operating Expenses | |||||||
| Research & Development | — | — | — | — | — | — | |
| Selling, General & Administrative | (1.73B) | (1.87B) | (1.61B) | (1.77B) | (1.97B) | 11.1% | |
| Depreciation & Amortization | (408.00M) | (437.00M) | (439.00M) | (493.00M) | (570.00M) | 15.6% | |
Operating Income (EBIT) | 2.38B | 1.43B | 1.26B | 1.35B | 1.60B | 19.1% | |
| Non-Operating Items | |||||||
| Interest Income | 1.00M | 10.00M | 11.00M | 25.00M | — | -100.0% | |
| Interest Expense | (152.00M) | (148.00M) | (163.00M) | (226.00M) | (264.00M) | 16.8% | |
| Other Income/Expenses (Net) | 296.00M | -149.00M | -106.00M | -152.00M | -243.00M | 59.9% | |
Income Before Tax | 2.68B | 1.28B | 1.16B | 1.19B | 1.36B | 13.9% | |
| Income Tax Expense | (597.00M) | (264.00M) | (248.00M) | (273.00M) | (314.00M) | 15.0% | |
Net Income | 2.00B | 946.00M | 854.00M | 871.00M | 992.00M | 13.9% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $16 | $8 | $8 | $8 | $9 | 13.7% | |
| Weighted Avg Shares Outstanding | 125.00M | 116.00M | 112.00M | 111.00M | 111.00M | 0.0% | |
| Weighted Avg Shares Outstanding (Diluted) | 128.00M | 118.00M | 113.00M | 113.00M | 113.00M | 0.0% | |
EBITDA | 3.16B | 1.82B | 1.73B | 1.89B | 2.19B | 15.8% |
Explore DGX
DGX in the Healthcare
Large Cap